Anti-MOG antibody disease (MOGAD): differentiation from AQP4 disorders
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Anti-MOG antibody disease (MOGAD): differentiation from AQP4 disorders. Lack of female preponderance. Fully referenced neurology checklist.
Clinical features supporting anti MOG
- Lack of female preponderance
- The presence of prodromal symptoms
- Concurrent acute disseminated encephalomyelitis (ADEM)
- More frequent monophasic course
- Lower risk of relapse
- Better outcome
Radiological features supporting anti MOG
Locked: subscribe to see this section.
Radiological features supporting AQP4
Locked: subscribe to see this section.
Radiological features supporting anti MOG and AQP4 equally
Locked: subscribe to see this section.
TRUE-MOGAD Score: ≥2 identifies MOGAD in people with MOG antibodies
Locked: subscribe to see this section.
References
- Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019; 76:301-309.
- Höftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015; 21:866-874.
- Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler 2020 (Epub ahead of print).
- Cobo-Calvo A, Ruiz A, Maillart E, et al; OFSEP and NOMADMUS Study Group. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology 2018; 90:e1858-e1869.
- Vilaseca A, Filippatou AG, Said Y, et al. TRUE-MOGAD Score: a novel scoring system to identify MOGAD among positive MOG-IgG test results. Neurol Neuroimmunol Neuroinflamm 2026; 13:e200563.
